LAUNXP Biomedical Co., Ltd (TPEX:6876)

Market Cap	407.31M -45.6%
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	32.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,457
Open	13.30
Previous Close	13.30
Day's Range	12.15 - 13.30
52-Week Range	9.09 - 25.45
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About LAUNXP Biomedical

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6876

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error